- Home
- BIIB vs RBLX Comparison
BIIB vs RBLX Comparison
Compare BIIB & RBLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- RBLX
- Stock Information
- Founded
- BIIB 1978
- RBLX 2006
- Country
- BIIB United States
- RBLX United States
- Employees
- BIIB N/A
- RBLX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- RBLX EDP Services
- Sector
- BIIB Health Care
- RBLX Technology
- Exchange
- BIIB Nasdaq
- RBLX Nasdaq
- Market Cap
- BIIB 18.7B
- RBLX 86.5B
- IPO Year
- BIIB 1991
- RBLX 2021
- Fundamental
- Price
- BIIB $144.86
- RBLX $133.36
- Analyst Decision
- BIIB Buy
- RBLX Strong Buy
- Analyst Count
- BIIB 27
- RBLX 23
- Target Price
- BIIB $188.09
- RBLX $125.32
- AVG Volume (30 Days)
- BIIB 1.5M
- RBLX 9.1M
- Earning Date
- BIIB 10-29-2025
- RBLX 10-30-2025
- Dividend Yield
- BIIB N/A
- RBLX N/A
- EPS Growth
- BIIB 31.67
- RBLX N/A
- EPS
- BIIB 10.45
- RBLX N/A
- Revenue
- BIIB $9,997,000,000.00
- RBLX $4,023,020,000.00
- Revenue This Year
- BIIB $2.00
- RBLX $68.52
- Revenue Next Year
- BIIB N/A
- RBLX $23.16
- P/E Ratio
- BIIB $13.86
- RBLX N/A
- Revenue Growth
- BIIB 3.36
- RBLX 27.39
- 52 Week Low
- BIIB $110.04
- RBLX $37.50
- 52 Week High
- BIIB $204.18
- RBLX $150.59
- Technical
- Relative Strength Index (RSI)
- BIIB 60.92
- RBLX 60.37
- Support Level
- BIIB $139.54
- RBLX $124.95
- Resistance Level
- BIIB $143.74
- RBLX $136.39
- Average True Range (ATR)
- BIIB 4.32
- RBLX 5.12
- MACD
- BIIB 0.69
- RBLX 0.53
- Stochastic Oscillator
- BIIB 71.89
- RBLX 82.39
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About RBLX Roblox Corporation
Roblox operates a free-to-play online video game platform with about 85 million daily active users. This platform has spawned a virtual universe and a Roblox economy based on the Robux currency. The platform houses millions of games from a wide range of creators spanning from young gamers themselves to professional development studios. Roblox offers creators the tools, publishing abilities, and platform for their games, enabling anyone to create a game. Creators earn money when gamers make optional in-game purchases within their games and by offering space for real-world advertising, and Roblox earns revenue primarily by taking a cut of these earnings.